RemeGen CoFRA:REG -2.42%39 Return-on-Tangible-Equity is 180.30% as of Dec. 2025. GuruFocus rates FRA:REG with a GF Score™ of 39/100 and a GF Value™ of €21.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,197 Biotechnology companies, RemeGen Co ranks better than 95.07% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. RemeGen Co's annualized net income for the quarter that ended in Dec. 2025 was €611.3 Mil. RemeGen Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €339.0 Mil. Therefore, RemeGen Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 180.30%.
The historical rank and industry rank for RemeGen Co's Return-on-Tangible-Equity or its related term are showing as below:
FRA:REG'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -56.29 Med: -29.72 Max: 47.97
Current: 47.97
During the past 8 years, RemeGen Co's highest Return-on-Tangible-Equity was 47.97%. The lowest was -56.29%. And the median was -29.72%.
FRA:REG's Return-on-Tangible-Equity is ranked better than 95.07% of 1197
companies
in the Biotechnology industry
Industry Median: -42.4
vs FRA:REG: 47.97
RemeGen Co (FRA:REG) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
RemeGen Co Return-on-Tangible-Equity Related Terms
RemeGen Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:REG vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, RemeGen Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 180.30% mean?
RemeGen Co (FRA:REG) has a Return-on-Tangible-Equity of 180.30% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #59 out of 1197 companies in the Biotechnology industry, placing it in the top 4.9%.
Is RemeGen Co's Return-on-Tangible-Equity too high?
RemeGen Co's current Return-on-Tangible-Equity is 180.30%. Based on the distribution chart, RemeGen Co ranks #59 out of 1197 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #59 out of 1197 companies for Return-on-Tangible-Equity. This places RemeGen Co in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on RemeGen Co and its competitors. RemeGen Co's current Return-on-Tangible-Equity is 180.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €21.08, compared to a current price of €9.36 — trading 55.6% below its estimated fair value. The current Return-on-Tangible-Equity is 180.30%. RemeGen Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Return-on-Tangible-Equity is 180.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.36 is trading 55.6% below its estimated GF Value™ of €21.08.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Return-on-Tangible-Equity: 180.30%
GF Value™: €21.08 vs. price of €9.36 (55.6% below fair value)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
39GF Score
Get the complete analysis for FRA:REG
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
